Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3655 Phase II in pre-cirrhotic NASH
CTR20210074Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NGM313 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Merck & Co.. Started Jan 2021; status: completed.
02
Drugs
NGM313
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20210074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210074.